229 related articles for article (PubMed ID: 28671297)
1. Standardisation of minimal residual disease in multiple myeloma.
Innao V; Allegra A; Russo S; Gerace D; Vaddinelli D; Alonci A; Allegra AG; Musolino C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28671297
[TBL] [Abstract][Full Text] [Related]
2. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic significance of sequencing-based MRD detection in multiple myeloma].
Takamatsu H
Rinsho Ketsueki; 2015 Aug; 56(8):989-96. PubMed ID: 26345557
[TBL] [Abstract][Full Text] [Related]
5. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
6. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.
Soh KT; Wallace PK
Curr Protoc Cytom; 2019 Sep; 90(1):. PubMed ID: 31608132
[TBL] [Abstract][Full Text] [Related]
8. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
9. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
11. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
Bergen HR; Dasari S; Dispenzieri A; Mills JR; Ramirez-Alvarado M; Tschumper RC; Jelinek DF; Barnidge DR; Murray DL
Clin Chem; 2016 Jan; 62(1):243-51. PubMed ID: 26430073
[TBL] [Abstract][Full Text] [Related]
12. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
13. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
14. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
[TBL] [Abstract][Full Text] [Related]
15. Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.
Avet-Loiseau H
Am Soc Clin Oncol Educ Book; 2016; 35():e425-30. PubMed ID: 27249750
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
Cedena MT; Martin-Clavero E; Wong S; Shah N; Bahri N; Alonso R; Barcenas C; Valeri A; Salazar Tabares J; Sanchez-Pina J; Cuellar C; Martin T; Wolf J; Lahuerta JJ; Martinez-Lopez J
PLoS One; 2020; 15(8):e0237155. PubMed ID: 32866200
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease analysis in myeloma - when, why and where.
Yanamandra U; Kumar SK
Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
[TBL] [Abstract][Full Text] [Related]
19. Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients.
Sata H; Shibayama H; Maeda I; Habuchi Y; Nakatani E; Fukushima K; Fujita J; Ezoe S; Tadokoro S; Maeda T; Mizuki M; Kosugi S; Nakagawa M; Ueda S; Iida M; Tokumine Y; Azenishi Y; Mitsui H; Oritani K; Kanakura Y
Exp Hematol; 2015 May; 43(5):374-381.e2. PubMed ID: 25591497
[TBL] [Abstract][Full Text] [Related]
20. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
